Evidence-based recommendations on HeartFlow FFRCT for estimating fractional flow reserve from coronary CT angiography.

Guidance development process

How we develop NICE medical technologies guidance

Next review: February 2020

Please note that the NICE guideline on chest pain was updated during the development of this guidance.

The clinical and cost evidence used to develop recommendations on HeartFlow FFRCT related to patients who would have been assessed, using previously recommended clinical scoring systems, as having a pre-test probability of intermediate risk (10% to 90%) of coronary artery disease.

Your responsibility

This guidance represents the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, healthcare professionals are expected to take this guidance fully into account. However, the guidance does not override the individual responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

Commissioners and/or providers have a responsibility to implement the guidance, in their local context, in light of their duties to have due regard to the need to eliminate unlawful discrimination, advance equality of opportunity, and foster good relations. Nothing in this guidance should be interpreted in a way that would be inconsistent with compliance with those duties.

Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible.

  • National Institute for Health and Care Excellence (NICE) accreditation logo